-
New contenders, category heavyweights battle for top spot in cough-cold
Last year, Drug Store News projected that GSK Consumer Healthcare’s Flonase allergy franchise would be challenged with the introduction of two new nasal corticosteroids to the market — McNeil Consumer’s Rhinocort and Bayer’s ClariSpray.
(To view the full Cough-Cold Report, click here.)
-
Nasal corticosteroids see high growth
While the C/A/S tablet and liquid subcategories have seen little change in sales versus year-ago sales, the UR nasal subcategory saw impressive growth in the channels studied, due in large part to the recent Rx-OTC switch products in the nasal corticosteroid segment, driving sales up 15% in the food industry and up to10% in drug. (see Figure 1).
(To view the full report, click here.)